BIO's 19.1% monthly rally is backed by digital PCR gains and steadier diagnostics, but weak Life Science demand and a rich valuation loom.

Qiagen (QGEN) has drawn fresh attention after surpassing its own sales and EPS outlook for Q2 2026 and reaffirming full year guidance, along with FDA clearance for its QIAstat Dx BCID GPF Plus AMR Panel. See our latest analysis for Qiagen. The recent Q2 beat, reaffirmed guidance and FDA clearance appear to have supported sentiment in Qiagen, with the stock at US$43.23 and a 90 day share price return of 31.08% contrasting with a year to date share price decline of 9.12% and a 1 year total...

Qiagen (NYSE:QGEN) walked into its second quarter of 2026 bracing investors for a roughly 2% sales decline. Instead, net sales came in flat at $535 million on August 6, and adjusted diluted EPS hit $0.62, both ahead of the company’s own outlook. For a diagnostics and life sciences supplier still working through the loss of […]

Zillow Group (NASDAQ:Z) delivered a second quarter that beat its own outlook on nearly every line, then turned around and eliminated jobs and reshuffled its leadership team. On the call held August 5, CEO Jeremy Wacksman and newly expanded COO and CFO Jeremy Hofmann laid out a business growing far faster than the housing market […]

Earlier this week, QIAGEN reported second-quarter 2026 results showing essentially flat year-on-year sales at US$535.04 million but higher net income of US$103.4 million, alongside shareholder-approved changes to its Articles that enable a reverse stock split and a capital repayment of up to US$200 million. On August 10, 2026, the company also secured U.S. FDA clearance for its QIAstat-Dx BCID GPF Plus AMR Panel, moving its QIAstat-Dx platform into bloodstream infection diagnostics and...

Sales beat guidance as Sample Technologies and QIAcuity drive growth momentum.

Evaluate Qiagen's (QGEN) reliance on international revenue to better understand the company's financial stability, growth prospects and potential stock price performance.

Qiagen (NYSE:QGEN) reported second-quarter 2026 results above its prior outlook, with net sales of $535 million, unchanged year over year on both a reported and constant-exchange-rate basis. The company had forecast an approximately 2% decline at constant exchange rates. Adjusted diluted earnings pe

Moby summary of Qiagen N.V.'s Q2 2026 earnings call

Qiagen (QGEN) delivered earnings and revenue surprises of +3.33% and +1.35%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

While the top- and bottom-line numbers for Qiagen (QGEN) give a sense of how the business performed in the quarter ended June 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.